Valuation: Nektar Therapeutics

Market Cap 2.1B 1.84B 1.7B 1.59B 2.97B 198B 3.03B 20.35B 7.88B 97.48B 7.87B 7.7B 339B P/E 2026 *
-6.85x
P/E 2027 * -5.6x
Enterprise Value 2.1B 1.84B 1.7B 1.59B 2.97B 198B 3.03B 20.35B 7.88B 97.48B 7.87B 7.7B 339B EV / Sales 2026 *
50.8x
EV / Sales 2027 * 56.8x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day-4.33%
1 week+1.72%
Current month-4.39%
1 month-6.88%
3 months-13.94%
6 months+41.17%
Current year+46.71%
1 week 61.45
Extreme 61.45
67.96
1 month 54.13
Extreme 54.13
67.96
Current year 33.4
Extreme 33.4
109
1 year 21.02
Extreme 21.02
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 2006-12-31
Director of Finance/CFO 60 2026-05-14
Chief Tech/Sci/R&D Officer 52 2015-06-30
Director TitleAgeSince
Director/Board Member 72 2000-07-31
Chairman 67 1992-04-30
Director/Board Member 73 2007-01-31
Date Insider Type Main position Quantity % Market Cap.
06-16Sell

Chief Executive Officer

-10,000 0.0296%
06-14Sell

Chief Technology Officer

-5,538 0.0164%
05-18Sell

Chief Technology Officer

-199 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-4.33%+1.72%+113.02%+612.25% 2.19B
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+19.37%+75.37%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
+2.03%+7.40%+28.79%-12.32% 17.01B
+0.88%+5.07%+28.91%-34.26% 15.91B
+0.68%+2.54%+22.28%+168.03% 13.29B
+3.02%+18.32%+141.11%+308.04% 13.58B
+0.79%+1.59%+85.06%+116.18% 11.75B
Average +0.98%+5.18%+54.19%+176.57% 22.28B
Weighted average by Cap. +1.93%+4.89%+50.22%+125.36%

Financials

2026 *2027 *
Net sales 41.22M 36.21M 33.36M 31.19M 58.5M 3.89B 59.57M 400M 155M 1.92B 155M 151M 6.66B 36.91M 32.42M 29.87M 27.93M 52.38M 3.48B 53.34M 358M 139M 1.72B 139M 136M 5.97B
Net income -250M -220M -202M -189M -355M -23.59B -361M -2.43B -940M -11.63B -939M -918M -40.42B -356M -313M -288M -269M -505M -33.57B -514M -3.45B -1.34B -16.55B -1.34B -1.31B -57.51B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
26-06-25 US$62.03 -4.33% 938,754
26-06-24 US$64.84 -2.77% 909,591
26-06-23 US$66.69 +1.51% 796,981
26-06-22 US$65.70 +7.74% 1,404,622
26-06-18 US$60.98 +0.10% 909,591
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
62.03USD
Average target price
153.25USD
Spread / Average Target
+147.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock